22 Pediatric Solid Tumors 1 1 0 26 26 9 http://clinicaltrials.dfhcc.harvard.edu/trials/9 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma RATIONALE: Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery. It is not yet known which regimen is more effective in treating soft tissue sarcoma. PURPOSE: This phase III trial is studying observation to see how well it works compared with radiation therapy, combination chemotherapy, and/or surgery in treating patients with soft tissue sarcoma. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 3 69 http://clinicaltrials.dfhcc.harvard.edu/trials/69 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, cyclophosphamide, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective when given together with radiation therapy in treating patients with rhabdomyosarcoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 3 208 http://clinicaltrials.dfhcc.harvard.edu/trials/208 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more tumor cells. PURPOSE: This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 3 219 http://clinicaltrials.dfhcc.harvard.edu/trials/219 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma RATIONALE: Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, no additional treatment is needed for the tumor until it progresses. In this case, observation may be sufficient. PURPOSE: This phase III trial is studying vincristine, carboplatin, and etoposide to see how well they work compared to observation only in treating patients who have undergone surgery for newly diagnosed retinoblastoma. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 3 283 http://clinicaltrials.dfhcc.harvard.edu/trials/283 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 3 365 http://clinicaltrials.dfhcc.harvard.edu/trials/365 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective in treating low-risk rhabdomyosarcoma. PURPOSE: This phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 3 19 http://clinicaltrials.dfhcc.harvard.edu/trials/19 Proton RT for the Treatment of Pediatric Rhabdomyosarcoma The main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. A beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. This means that less healthy tissue is affected by proton beam radiation than by photon beam radiation. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 2 41 http://clinicaltrials.dfhcc.harvard.edu/trials/41 Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas The main purpose of this study is to assess the short term and the long term side effects of proton beam radiation for pediatric bone and non-rhabdomyosarcoma soft tissue sarcomas. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 2 136 http://clinicaltrials.dfhcc.harvard.edu/trials/136 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors RATIONALE: Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 2 194 http://clinicaltrials.dfhcc.harvard.edu/trials/194 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 2 260 http://clinicaltrials.dfhcc.harvard.edu/trials/260 Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 2 79 http://clinicaltrials.dfhcc.harvard.edu/trials/79 Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 1 111 http://clinicaltrials.dfhcc.harvard.edu/trials/111 Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs. PURPOSE: This laboratory study is looking at the pharmacokinetics of daunorubicin in treating young patients with cancer. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors N/A 114 http://clinicaltrials.dfhcc.harvard.edu/trials/114 Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET) RATIONALE: Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function in young patients with cancer. PURPOSE: This clinical trial is studying neuropsychological and behavioral testing in young patients with medulloblastoma or supratentorial primitive neuroectodermal tumor (PNET). Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 121 http://clinicaltrials.dfhcc.harvard.edu/trials/121 Evaluating Dactinomycin and Vincristine in Young Patients With Cancer RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how dactinomycin and vincristine affect the body and how patients will respond to treatment. PURPOSE: This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors N/A 212 http://clinicaltrials.dfhcc.harvard.edu/trials/212 Study of Late-Occurring Complications in Childhood Cancer Survivors RATIONALE: A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. PURPOSE: This clinical trial is studying cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 258 http://clinicaltrials.dfhcc.harvard.edu/trials/258 Study of Kidney Tumors in Young Patients RATIONALE: Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at kidney tumors in young patients. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors N/A 1184 http://clinicaltrials.dfhcc.harvard.edu/trials/1184 Sunitinib in Treating Young Patients With Refractory Solid Tumors RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 1197 http://clinicaltrials.dfhcc.harvard.edu/trials/1197 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus) The purpose of this study is to determine whether maintenance therapy with oral AP23573 (ridaforolimus), by preventing and controlling tumor growth for a prolonged period of time in patients with metastatic soft-tissue or bone sarcomas responding to chemotherapy, will result in clinically significant improvement in progression-free survival as compared to oral placebo. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 1224 http://clinicaltrials.dfhcc.harvard.edu/trials/1224 Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors RATIONALE: Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of aflibercept in treating young patients with relapsed or refractory solid tumors. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 1240 http://clinicaltrials.dfhcc.harvard.edu/trials/1240 MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia RATIONALE: MLN8237 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of MLN8237 and to see how well it works in treating young patients with relapsed or refractory solid tumors or acute lymphoblastic leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 1246 http://clinicaltrials.dfhcc.harvard.edu/trials/1246 A Study of Aprepitant (MK0869) and Fosaprepitant (MK0517) in Pediatric Patients Receiving Chemotherapy This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy induced nausea and vomiting in pediatric patients from 6 months to 17 years of age. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 1336 http://clinicaltrials.dfhcc.harvard.edu/trials/1336 Cixutumumab and Temsirolimus in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment RATIONALE: Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of cixutumumab when given together with temsirolimus in treating young patients with solid tumors that have recurred or not responded to treatment. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 1431 http://clinicaltrials.dfhcc.harvard.edu/trials/1431 Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and best dose of zoledronic acid when given together with combination chemotherapy in treating patients with newly diagnosed metastatic osteosarcoma. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma 1439 http://clinicaltrials.dfhcc.harvard.edu/trials/1439 Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Not Responded to Treatment RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have not responded to treatment. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 1440 http://clinicaltrials.dfhcc.harvard.edu/trials/1440 Ecteinascidin 743 in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors RATIONALE: Drugs used in chemotherapy such as ecteinascidin 743 use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ecteinascidin 743 works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors